Cilostazol
Platelet Aggregation Inhibitors Excl. Heparin
- Drug class
- Platelet Aggregation Inhibitors Excl. Heparin
- Availability
- Prescription only
- Routes
- Oral
- Markets covered
- 2
- Products on record
- 5
- FDA reports (12 mo)
- 251
Overview
Plain-language summary, compiled from the cited regulatory records
Cilostazol is a medication that works by inhibiting phosphodiesterase III (PDE III) [1]. It belongs to the drug class of platelet aggregation inhibitors, excluding heparin [1].
The approved use for cilostazol tablets is to reduce the symptoms associated with intermittent claudication. This condition is characterized by leg pain during physical activity, and cilostazol has been shown to increase walking distance in individuals experiencing these symptoms [1].
In the past 12 months, there have been 251 adverse event reports associated with cilostazol [2]. Common adverse events reported include diarrhea, nausea, dyspnea, pneumonia, and off-label use [2].
This is not medical advice. Consult a qualified healthcare professional.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 3 | May 22, 2026 |
| US United States | FDA | 2 | April 12, 2024 |
GBUnited Kingdom· MHRA
3 products
Uses
Cilostazol is indicated for the improvement of the maximal and pain-free walking distances in patients with intermittent claudication, who do not have rest pain and who do not have evidence of peripheral tissue necrosis (peripheral arterial disease Fontaine stage II).
Cilostazol is for second-line use, in patients in whom lifestyle modifications (including stopping smoking and [supervised] exercise programs) and other appropriate interventions have failed to sufficiently improve their intermittent claudication symptoms.
How to take
USUnited States· FDA
2 products
Uses
1 INDICATIONS AND USAGE Cilostazol tablets are indicated for the reduction of symptoms of intermittent claudication, as demonstrated by an increased walking distance. Cilostazol is a phosphodiesterase III inhibitor (PDE III inhibitor) indicated for the reduction of symptoms of intermittent claudication, as demonstrated by an increased walking distance ( 1 )
How to take
Drug interactions
Known interactions involving Cilostazol. Select one for details. This list is informational and not a complete interaction checker.
Showing 240 of 392. Type above to find a specific drug.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PL045691426 · revised May 22, 2026
- [2]FDA DailyMed · 15478d90-312f-01… · revised April 4, 2024 [PDF]
- [3]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.